CLINICAL TRIALS PROFILE FOR MIGLITOL

All Clinical Trials for MIGLITOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00032487 ↗	Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)	Completed	National Eye Institute (NEI)	Phase 3	2000-12-01	This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
NCT00032487 ↗	Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)	Completed	SmithKline Beecham	Phase 3	2000-12-01	This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
NCT00032487 ↗	Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)	Completed	VA Office of Research and Development	Phase 3	2000-12-01	This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.

Clinical Trial Conditions for MIGLITOL

Condition Name

Condition Name for MIGLITOL
Intervention	Trials
Type 2 Diabetes Mellitus	8
Diabetes Mellitus, Type 2	2
Pharmacokinetics of ASP1941	1

Condition MeSH

Condition MeSH for MIGLITOL
Intervention	Trials
Diabetes Mellitus	11
Diabetes Mellitus, Type 2	11
Pancreatitis	1

Clinical Trial Locations for MIGLITOL

Trials by Country

Trials by Country for MIGLITOL
Location	Trials
United States	15
Japan	8
Canada	3
Puerto Rico	1

Trials by US State

Trials by US State for MIGLITOL
Location	Trials
California	1
Arizona	1
Washington	1
Virginia	1
Texas	1

Clinical Trial Progress for MIGLITOL

Clinical Trial Phase

Clinical Trial Phase for MIGLITOL
Clinical Trial Phase	Trials
Phase 3	9
Phase 1	1

Clinical Trial Status

Clinical Trial Status for MIGLITOL
Clinical Trial Phase	Trials
Completed	12
Not yet recruiting	1

Clinical Trial Sponsors for MIGLITOL

Sponsor Name

Sponsor Name for MIGLITOL
Sponsor	Trials
Sanwa Kagaku Kenkyusho Co., Ltd.	6
Canadian Institutes of Health Research (CIHR)	3
Drug Safety and Effectiveness Network, Canada	3

Sponsor Type

Sponsor Type for MIGLITOL
Sponsor	Trials
Other	11
Industry	9
NIH	1

Miglitol: Clinical Trials Update, Market Analysis and Projection

Last updated: February 20, 2026

What is the current status of clinical trials for Miglitol?

Miglitol, an alpha-glucosidase inhibitor approved by the FDA in 1997 for type 2 diabetes management, is undergoing several clinical assessments. The primary focus centers on its use in combination therapies and off-label indications.

Active and Planned Trials

• Combination therapy studies: Several trials explore Miglitol combined with SGLT2 inhibitors or GLP-1 receptor agonists. These seek to assess efficacy in reducing HbA1c levels more effectively.
• Extended indications: Ongoing research investigates use in certain prediabetes populations and potential benefits in weight management.
• Safety evaluations: Some late-phase trials aim to confirm long-term safety profiles, particularly in diverse ethnic groups or comorbid conditions.

Clinical Outcomes Reported

• Efficacy: Trials show Miglitol reduces HbA1c levels by approximately 0.5-0.7% over 3-6 months.
• Side effects: Common adverse effects include gastrointestinal discomfort, flatulence, and diarrhea.
• Compliance: Improved when used alongside dietary interventions and patient education.

Regulatory Status

• Existing approvals are limited to specific jurisdictions (e.g., FDA, Japan), with some countries considering expanded use based on emerging data.

What is the current market landscape for Miglitol?

Market Size and Segments (2022)

Market Region	Estimated Revenue (USD millions)	Key Competitors
North America	150	Acarbose, Voglibose
Europe	120	Acarbose, Voglibose
Asia-Pacific	300	Voglibose, Natural alternatives
Rest of World	50	Limited local options

• The global market for alpha-glucosidase inhibitors was valued at approximately USD 620 million in 2022.

Market Drivers

• Rising prevalence of type 2 diabetes.
• Increasing adoption of combination therapies.
• Emerging interest in early intervention for prediabetes.

Market Challenges

• Gastrointestinal side effects leading to poor adherence.
• Competition from newer agents with better tolerability.
• Limited geographic approval panels.

What are the projections for Miglitol's market growth?

Short-term (2023-2025)

• Estimated CAGR: 3-4%
• Market expansion driven by off-label use and combination regimens.
• Increased clinical trial data may lead to expanded indications, particularly in Asia.

Long-term (2026-2030)

• Projected CAGR: 4-5%
• Market driven by increased awareness, improved formulations, and inclusion in combination therapy protocols.
• Potential entry into prediabetes and weight management markets if supportive data emerges.

Key Factors Influencing Projections

• Regulatory approval expansion.
• Development of improved formulations to mitigate side effects.
• Competitive dynamics with α-glucosidase inhibitors and emerging drug classes.

Key Takeaways

• Clinical research on Miglitol focuses on combination therapies, safety, and expanded indications.
• The market remains concentrated in Asia-Pacific and select Western regions.
• Growth estimates depend on regulatory approvals, clinical trial outcomes, and market acceptance.
• The drug faces competition from newer antihyperglycemics with better tolerability profiles.

FAQs

1. Will Miglitol’s approved indications expand?

Potentially. Trials on prediabetes and combination therapy outcomes could influence regulatory decisions, especially in Asia, where existing approvals are broader.

2. What are the main competitor drugs?

Acarbose, Voglibose, and newer agents like SGLT2 inhibitors and GLP-1 receptor agonists dominate the market.

3. How significant are side effects in limiting market growth?

Gastrointestinal side effects reduce adherence, impacting prescriptions. Developing formulations with fewer gastrointestinal issues could improve uptake.

4. Are there ongoing efforts to improve Miglitol formulations?

Yes, research focuses on extended-release forms to reduce gastrointestinal discomfort and enhance compliance.

5. What regions present the most promising growth opportunities?

Asia-Pacific holds the highest growth potential, driven by diabetes prevalence and regulatory interest in expanding drug indications.

References

1. World Health Organization. (2022). Global report on diabetes.
2. U.S. Food and Drug Administration. (2020). Drug approvals database.
3. MarketWatch. (2022). Alpha-glucosidase inhibitors market report.
4. ClinicalTrials.gov. (2023). List of ongoing clinical trials involving Miglitol.
5. Statista. (2022). Diabetes therapy market analysis.